Nari GA y cols. Resultados de corto plazo del tratamiento quirúrgico de tumores retroperitoneales. Rev Argent Cir. 2026;118(2):e-1924  
5
1
8
del 35% ha sido informada por algunos autores .  
El neuroblastoma ꢀene su origen en las células  
La supervivencia tuvo una mediana de 60 me- pluripotenciales del sistema simpáꢀco, es frecuente en  
ses. Este dato en parꢀcular debe ser tomado cuida- recién nacidos y es un tumor relaꢀvamente raro, pero  
dosamente, ya que está basado en resultados de un el retroperitoneo suele ser el siꢀo de aparición más co-  
grupo heterogéneo de tumores y algunos de ellos eran mún. La cirugía incompleta de estas lesiones suele estar  
benignos. La supervivencia global informada en sarco- asociada a mal pronósꢀco, al igual que la edad de pre-  
2
6
mas retroperitoneales es similar a la comunicada por sentación .  
4
nosotros .  
El PEComa (perivascular epithelioid cell tumor),  
La uꢀlización de la radioterapia en tumores anteriormente conocido como angiomiolipoma extra-  
malignos está condicionada en primer lugar por las ca- rrenal, es un tumor muy poco frecuente, de caracte-  
racterísꢀcas espaciales que implica el retroperitoneo, rísꢀcas benignas y para el cual la cirugía de resección  
8
aunque probablemente con técnicas como la 3D-CRT o completa es el tratamiento definiꢀvo .  
el uso de la IMRT se podrían proteger los tejidos perifé-  
ricos al siꢀo para irradiar .  
Finalmente, hemos uꢀlizado la biopsia por  
punción histológica (core) en solo 5 de los pacientes  
1
9
1
9
Diamanꢀs y cols. refieren que la radioterapia resecados, y fue posiꢀva tan solo en uno de ellos. Está  
podría mejorar los resultados en algunos ꢀpos especia- demostrado que este ꢀpo de biopsia ꢀene mejores re-  
2
0
les de lesiones. Por otro lado, el estudio STRASS falló sultados en los sarcomas, aunque la dificultad diagnós-  
en demostrar algún ꢀpo de mejoría en los resultados ꢀca se incrementa cuando son bien diferenciados; algu-  
cuando se asocia la radioterapia. Otros autores refieren nos autores refieren un bajo índice de complicaciones  
2
7
que la radioterapia tendría un papel dentro de la neo- menores que ronda el 10% .Creemos que esta biopsia  
2
1
adyuvancia de sarcomas que son resecables . La qui- debe incorporarse dentro del arsenal diagnósꢀco.  
mioterapia, por su parte, parece no tener resultados fa- En los tumores retroperitoneales malignos, la  
vorables desde ningún punto de vista en el tratamiento radioterapia y la quimioterapia ꢀenen una uꢀlidad du-  
2
2,23  
de los sarcomas retroperitoneales . El tumor miofi- dosa. En sarcomas, en parꢀcular, la resección R0 que  
broblásꢀco inflamatorio retroperitoneal es extremada- incluya, si fuera necesaria la resección visceral o vas-  
mente raro; su principal siꢀo de localización suele ser el cular, el estado nutricional y el grado propuesto por  
pulmón y ocurre más frecuentemente en niños. Si bien la FFCCSG son las variables que más se asocian con el  
es un tumor benigno, ꢀene potencialidad de converꢀr- pronósꢀco.  
se en maligno y dar metástasis a distancia. La cirugía es  
Nuestro estudio presenta las siguientes limita-  
el único tratamiento eficaz para erradicarlo; como en ciones: su diseño retrospecꢀvo, sobre pacientes atendi-  
el resto de los tumores malignos, la quimioterapia y la dos durante varios años, un pequeño tamaño muestral  
radioterapia no han aportado diferencias comparadas y una composición heterogéna de los ꢀpos histológicos,  
2
4
con la cirugía .  
El schwannoma es, al igual que el anterior, un  
acorde con su baja frecuencia.  
En conclusión, en la serie aquí presentada, la  
tumor benigno con potencial maligno que puede estar mayoría de los tumores retroperitoneales fueron ma-  
asociado a neurofibromatosis. También ꢀene la parꢀ- lignos y principalmente sarcomas. La cirugía con resec-  
cularidad de alcanzar tamaños importantes y ejercer ción R0 pudo ser obtenida en un alto porcentaje de los  
efecto masa. El tratamiento es siempre quirúrgico y la casos, con una tasa de complicaciones comparable a las  
2
5
recurrencia es infrecuente .  
comunicadas en otras series.  
■
ENGLISH VERSION  
Introducꢀon  
Retroperitoneal  
for these paꢀents, as some tumors exhibit a locally  
aggressive behavior, resulꢀng in a high percentage of  
4
tumors  
include  
a
local recurrences . With a few excepꢀons, neoadjuvant  
heterogeneous group of soꢁ-ꢀssue tumors originaꢀng and adjuvant chemotherapy and/or radiaꢀon therapy  
from different cell lineages. These tumors can be benign do not generally improve survival rates.  
or malignant, while some exhibit an intermediate  
The aim of the present study was to evaluate  
1
behavior . Most retroperitoneal tumors are malignant, the short-term outcomes of surgical resecꢀon of  
with sarcomas being the most common type. Within retroperitoneal tumors.  
this laꢂer group, liposarcomas are the most common  
in most series¹⁻³. Retroperitoneal tumors are generally  
large, andtheclinicalpresentaꢀonassociatedwiththese Material and methods  
lesions is oꢁen related to the mass effect. However, the  
3
incidence of distant metastasis is relaꢀvely low . Overall,  
We conducted an observaꢀonal, retrospecꢀve  
complete surgical resecꢀon offers the best outcomes and descripꢀve study. We retrieved data from the  
6
Nari GA y cols. Resultados de corto plazo del tratamiento quirúrgico de tumores retroperitoneales. Rev Argent Cir. 2026;118(2):e-1924  
medical records of paꢀents referred for surgery tumors, and  
7
of them were sarcomas.  
between January 2005 and December 2024 due to  
Complicaꢀons occurred in 4 cases: 2 surgical  
retroperitoneal tumors. Parꢀcipants were excluded site infecꢀons, 1 seroma near the surgical incision, and  
from the study if they had not undergone surgery 1 case of pneumonia associated with pleural effusion,  
or for whom insufficient data was available. Tumors which prolonged the length of hospital stay for clinical  
originaꢀng in retroperitoneal organs or lymphaꢀc management. Table 2 describes the postoperaꢀve  
ꢀ
ssue—primarily lymphomas—were also excluded.  
findings.  
The pathological diagnoses are detailed in  
The data recorded included demographic,  
clinical, pathological, and operaꢀve variables. Table 3. The most representaꢀve cases of this series are  
Complicaꢀons were categorized using the Clavien- shown in Figures 2 to 5.  
Dindo classificaꢀon5. Survival was expressed in months  
and tracked unꢀl the date of death. For paꢀents  
who were lost to follow-up, their survival status was  
verified in the Renaper database (Registro Nacional  
de Personas. Argenꢀna.gob.ar). Length of hospital stay  
was measured in days.  
Data were entered into a reference table  
for staꢀsꢀcal analysis. Qualitaꢀve variables were  
expressed in range, frequency and percentage and  
quanꢀtaꢀve variables were expressed in range, median  
and standard deviaꢀon (SD).  
■ TABLE 1  
Demographic and preoperaꢀve clinical variables  
Variable  
Male sex (n)  
Age (range) (Median - SD)  
8
66.6%  
42 ± 14.96  
19-61  
Symptoms  
Abdominal pain (n)  
Weight loss (n)  
12  
8
100%  
66.6%  
58.3%  
66.6%  
58.3%  
Nausea and vomiꢀng (n)  
Distension (n)  
7
8
Palpable mass (n)  
7
Family history  
7
58.3%  
Results  
Laboratory tests  
Blood albumin level (range) (Median - SD) 2.9-3.4  
3.25 ± 0.16  
11.5 ± 1  
41.6%  
During the study period, 19 paꢀents with  
retroperitoneal tumors were treated. Of these, 7  
were excluded from the analysis: 4 were considered  
unresectable during preoperaꢀve assessment, 2 were  
found to be unresectable intraoperaꢀvely, and one  
paꢀent did not have the minimum data required for  
inclusion in the study (Fig. 1).  
Thus, 12 paꢀents with retroperitoneal tumors  
who underwent curaꢀve intent surgery were included  
for the analysis. The demographic, clinical, and  
pathological variables are presented in Table 1.  
malignant  
Hemoglobin (range) (Median - SD)  
Tumor markers (n)  
10-13  
5
Performance Status  
0
1
(n)  
(n)  
9
3
4
75%  
25%  
Sarcopenia (n)  
33.3%  
Ancillary tests  
Ultrasound (n)  
12  
12  
10  
3
100%  
100%  
83.3%  
25%  
Computed tomography scan (n)  
MRI (n)  
Colonoscopy (n)  
Upper gastrointesꢀnal endoscopy (n)  
6
50%  
Needle biopsy (n)  
5
41.6%  
Size Maximum diameter (range)  
Needle biopsy results  
5-30 cm  
1 (+) 4 (-)  
16.9 cm  
Eight  
paꢀents  
presented  
■
FIGURE 1  
Flowchart. Type of tumors and exclusion  
criteria  
Retroperitoneal tumors  
19 patients)  
(
7
excluded  
1
2 included  
Lack of data 1  
Unresectability 6  
Malignant tumors 8  
Potentially malignant 3  
Benign tumor 1  
•
•
•
Liposarcoma 2  
Rhabdomyosarcoma 1  
Unknown origin 3  
Nari GA y cols. Resultados de corto plazo del tratamiento quirúrgico de tumores retroperitoneales. Rev Argent Cir. 2026;118(2):e-1924  
7
results are consistent with those of papers that focus  
solely on retroperitoneal sarcomas.  
An R0 resecꢀon is essenꢀal because it is  
strongly associated with a lower recurrence rate and  
improved survival.  
■
TABLE 2  
Surgical and postoperaꢀve variables  
Variable  
Resecꢀon  
R0 (n)  
8
3
72.7%  
27.2%  
8.33%  
Mulꢀorgan resecꢀon, as well as vascular  
resecꢀon, should be performed if necessary to achieve  
an R0 resecꢀon, as it improves survival with mortality  
rates similar to those of procedures that do not involve  
R1 (n)  
Resecꢀon of more than one organ (n)  
Clavien-Dindo  
Grade 1 (n)  
Grade 2 (n)  
1
3
1
25%  
8.3%  
resecꢀon of other organs or vascular resecꢀon, but  
with higher morbidity rates1  
,3,4,11  
.
Length of hospital stay (days), (Median-SD)  
Tumor recurrence (n)  
3-9  
3
6.5 (± 1.78)  
25%  
Adjuvant treatment (n)  
3
25%  
■ FIGURE 2  
Follow-up in months (range), (Median-SD)  
4-96  
60 (±39)  
■
TABLE 3  
Pathological variables  
Variable  
n
%
Histological types  
Liposarcoma  
4
1
1
1
33.3  
8.3  
8.3  
8.3  
Hisꢀocyꢀc sarcoma  
Synovial sarcoma  
High-grade solid sarcoma  
Teratocarcinoma  
Neuroblastoma  
Magneꢀc resonance imaging (MRI) showing a large inflammatory  
myofibroblasꢀc tumor  
1
1
1
1
1
8.3  
8.3  
8.3  
8.3  
8.3  
Schwannoma  
Myofibroblasꢀc sarcoma  
Inflammatory sarcoma  
PEComa  
■ FIGURE 3  
Cell differenꢀaꢀon  
Low-grade  
3
1
8
25  
8.3  
High-grade  
Not reported  
66.6  
Immunohistochemistry  
8
66.6  
Discussion  
Retroperitoneal tumors comprise a highly  
heterogeneous group of soꢁ-ꢀssue tumors located in  
1
,6–9  
MRI showing a liposarcoma  
the retroperitoneal space . For this reason, mulꢀple  
classificaꢀon systems have been developed. To our  
understanding, the best classificaꢀon for these lesions  
is one that categorizes tumors based on the ꢀssue  
from which they originate (mesenchymal or germ cell,  
among others), with a further subdivision into benign  
■
FIGURE 4  
9
and malignant tumors . The most recent classificaꢀon  
by the World Health Organizaꢀon (WHO) for soꢁ ꢀssue  
tumors is also widely used10. Of the 12 cases that  
underwent surgery, 8 paꢀents had malignant tumors, 7  
of which were sarcomas. These findings are consistent  
with the reports of most authors, with liposarcomas  
1
-3  
being the most common tumors . Due to the  
heterogeneity of the series presented here, we will first  
address some general aspects of malignant tumors and  
then discuss specific consideraꢀons regarding benign  
tumors.  
An R0 resecꢀon was achieved in 8 of 11  
potenꢀally malignant cases (72.7%). Although this  
study has examined all retroperitoneal tumors, these  
Computed tomography and surgical specimen of liposarcoma  
8
Nari GA y cols. Resultados de corto plazo del tratamiento quirúrgico de tumores retroperitoneales. Rev Argent Cir. 2026;118(2):e-1924  
■
FIGURE 5  
A. Computed tomography images. B.  
Inferior vena cava pushed forward and  
opening of the right renal vein (black  
arrow), both pushed forward by the  
tumor (black arrowhead). C. The liver  
is above (black arrow) and a gauze is  
occupying the site where the tumor was  
located (black arrowhead); the kidney  
(
white arrow), right renal vein, and vena  
cava are completely released (white  
arrowheads).  
A noteworthy observaꢀon in this context is for retroperitoneal sarcomas is similar to ours4.  
that, in approximately 26% of paꢀents where invasion The use of radiaꢀon therapy for malignant  
of adjacent organs is not suspected, histopathologic tumors is primarily determined by the anatomical  
invasion is present. This finding underscores the characterisꢀcs of the retroperitoneum, although  
necessity for meꢀculous aꢂenꢀon to ensure wider techniques such as 3D-CRT or IMRT could likely be  
1
2
margins to facilitate complete resecꢀons . Regarding used to protect the surrounding normal ꢀssues from  
1
9
liposarcomas, Lee et al. reported that disease-free radiaꢀon .  
1
3
Diamanꢀs et al.19 reported that radiaꢀon  
survival did not differ between R0 and R1 resecꢀons .  
Some authors suggest that, when comparing therapy could improve outcomes for specific types  
R2 resecꢀons with non-surgical management, paꢀents of lesions. The STRASS study20 failed to demonstrate  
who underwent resecꢀon had beꢂer outcomes any improvement in outcomes when combined with  
compared to those without resecꢀon radiaꢀon therapy. Other authors stated that radiaꢀon  
As previously menꢀoned, it is crucial to note therapy could play a role in the neoadjuvant treatment  
1
4-16  
.
2
1
that symptoms are frequently associated with the of resectable sarcomas . Chemotherapy does not  
mass effect. Consequently, in young paꢀents with seem to have favorable outcomes from any perspecꢀve  
good performance status, an R2 resecꢀon may be in the treatment of retroperitoneal sarcomas22,23  
.
recommended for palliaꢀve purposes, thereby offering Retroperitoneal inflammatory myofibroblasꢀc tumors is  
temporary relief from symptoms.  
an extremely rare condiꢀon; they primarily occur in the  
There were four complicaꢀons in our series lungs and are more common in children. Although these  
(33.3%), a figure that, like the mortality rate, falls within tumors are benign, they have the potenꢀal to become  
1
,4  
the range reported by other authors . It is reasonable malignant and metastasize to distant sites. Surgery is  
to expect that complicaꢀons will be more common in the only effecꢀve treatment for eradicaꢀng the tumor.  
paꢀents with tumors that invade adjacent structures, As with other malignant tumors, chemotherapy and  
especially major vessels, or in paꢀents undergoing radiaꢀon therapy have not shown any advantage over  
2
4
resecꢀons that involve other organs. Paꢀents’ surgery .  
nutriꢀonal condiꢀons and sarcopenia should also be  
assessed when deciding to indicate surgery, as these the potenꢀal to become malignant and may be  
factors contribute to greater morbidity and mortality . associated with neurofibromatosis. They can reach  
The recurrence rate in our series was 25%, large dimensions and produce mass effect. Surgery is  
but some paꢀents were not followed up by us. always indicated and recurrences are rare .  
Other authors have reported a recurrence rate of  
Schwannomas are also benign tumors with  
1
7
2
5
Neuroblastomas originate in pluripotent cells  
1
8
approximately 35% .  
of the sympatheꢀc nervous system. These relaꢀvely  
Median survival was 60 months. It is essenꢀal rare tumors occur in newborns and are most commonly  
to interpret this finding with cauꢀon, as it is based on found in the retroperitoneum. Incomplete surgical  
results from a heterogeneous group of tumors, some of treatment of these lesions and the age at presentaꢀon  
2
6
which were benign. The overall survival rate reported are usually associated with a poor prognosis .  
Nari GA y cols. Resultados de corto plazo del tratamiento quirúrgico de tumores retroperitoneales. Rev Argent Cir. 2026;118(2):e-1924  
9
PEComa (perivascular epithelioid cell tumor), tumors is uncertain. For sarcomas, R0 resecꢀons—  
formerly known as extrarenal angiomyolipoma, is a including visceral or vascular resecꢀon if necessary—  
rare benign tumor. Complete surgical resecꢀon is the nutriꢀonal condiꢀons, and the grade proposed by the  
8
definiꢀve treatment for this condiꢀon .  
FFCCSG are the variables most strongly associated with  
Finally, we performed a core needle biopsy prognosis.  
on only 5 of the paꢀents who underwent resecꢀon,  
Our study is subject to the following limitaꢀons:  
and it was posiꢀve in only one of them. It has been it was retrospecꢀve, covering paꢀents treated over  
demonstrated that this type of biopsy yields superior several years; it had a small sample size; and it included  
results in cases of sarcoma, although the diagnosis a heterogeneous composiꢀon of histological types,  
may be complicated in well-differenꢀated sarcomas. consistent with their low prevalence.  
Some authors report a low rate of minor complicaꢀons,  
In conclusion, most of the retroperitoneal  
around 10% . We believe that this biopsy should be tumors presented in this series were malignant,  
included in the diagnosꢀc workup. primarily sarcomas. R0 resecꢀons were achieved in  
2
7
The value of radiaꢀon therapy and a high percentage of cases, with a complicaꢀon rate  
chemotherapy in treaꢀng malignant retroperitoneal comparable to that reported in other series.  
Referencias bibliográficas /References  
1
.
Guo Q, Zhao J, Du X, Huang B. Survival outcomes of surgery for  
retroperitoneal Sarcomas. A systemaꢀc review and meta-analysis.  
16. Lehnert T, Cardona S, HinzU, Willeke F, Mechtersheimer G,  
Treiber M, et al. Primary and lovally recurrent retroperitoneal  
soꢁ-ꢀssue sarcoma: local control and survival. Eur  
2
3
.
.
Mack T, Purgina B. Updates in pathology for retroperitoneal soꢁ  
17. Nasirishargh A, Grova M, Bateni C, Judge S, Nuno M, Basmaci  
U,et al. Sarcopenia and frailty as predictors of surgical morbidity  
Santangelo A, Fernicola A, Santangelo D, Peluso G, Calogero A,  
Croceꢂo F, et al. Dark topics on giant retroperitoneal liposarcoma:  
and oncologic outcomes in retroperitoneal sarcomas.  
Surg Oncol. 2023;127:855-61  
18. Deng H, Cao B, Cui H, Chen R, Li H, Zhao R, et al. Clinical analysis  
of 5-year survival and recurrence in giant retroperitoneal  
4
5
6
.
.
.
Hu H, Guo Q, Zhao J, Huang B, Du X. Agressive surgical approach  
with vascular resecꢀon and reconstrucꢀon for retroperitoneal  
19. Diamanꢀs A, Baloyiannis I, Magoulioꢀs D, Tolia M, Symeonidis D,  
Bompou E, et al. Perioperaꢀve radiotherapy versus surgery alone  
for retroperitoneal sarcomas: asystemaꢀc review and meta-  
20. Bonvalot S, Gronchi A, Le Péchoux C, Swallow C, Strauss D,  
Meeus P, et al. Preoperaꢀve radiotherapy plus surgery versus  
surgery alone for paꢀents with primary retroperitoneal Sarcoma  
(EORTC-62092: STRASS): amulꢀcentre, open-label, randomized,  
phase 3 trial. Lancet Oncol. 2020;21(10):1366-77.doi: 10.1016/  
S1470-2045(20)30446-0.  
21. Daꢂa J, Ecker B, Neuwirth M, Geha R, Fraker D, Roses R, et al.  
Contemporaryreappraisaloftheefficacyofadjuvantchemotherapy  
in resected retroperitoneal sarcoma: Evidence from naꢀonwide  
22. Zhou D, Connolly E, Mar J, Lazarakis S, Grimison P, Connor J, et al. A  
systemaꢀc review of the role of chemotherapy in retroperitoneal  
Clavien P, Barkun J, de Oliveira M, Vauthey J, Dindo D, Schulick R,  
et al. The Clavien-Dindo classificaꢀon of surgical complicaꢀons:  
Ogose A, Kawashima H, Hatano H, Ariizumi T, Sasaki T, Tamagishi  
T, et al. The natural history of incidental retroperitoneal  
7
.
Aꢃli S, Chandra CR, Hemant DK, Bapsy P, Rama Rao C, Anupama  
Nari G, Brandan Recalde E, German G, Rojo S, Carreras M, Lasso  
Molina D. Neoplasia de células epitelioides perivasculares subꢀpo  
angiomiolipoma de localización retroperitoneal. Oncología  
Clínica. 2019;24:65-8.  
Apestegui CA. Tumores retroperitoneales. Relato oficial. 69.°  
Congreso Argenꢀno de Cirugía. Rev Argent Cirug. 1998; N.°  
Extraordinario: 75-167.  
8
.
9
1
1
.
sarcoma by the Australian  
and New Zeeland Sarcoma  
0. Choi Jh, Ro JY. The 2020 WHO classificaꢀon of tumors of soꢁ  
associaꢀonclinical pracꢀce guidelines working party. Cancer  
ꢀ
1. Paik B, Ceo CJ, Tan J, Juan WKD, Soo KC, Ong C, et al. Asystemic  
review of margin status in retroperitoneal liposarcomas: does  
2. Fairweather M, Wang J, JoV, Valdini E, Bertagnolli M, Rait C.  
Surgical management of primary retroperitoneal sarcomas:  
23. Aꢃli S, Chandra R, Hemant D, Bapsy P, RamaRao C, Anupama  
G. Retroperitoneal inflammatory myofibroblasꢀc tumor. World  
1
24. Alventosa Mateu C, Casꢀllo López G, Alcert Antequera C.  
25. Liu X, Zhao J, Zhang L, Huang J, Ma Y. The effect of age  
distribuꢀon on the prognosis of retroperitoneal neuroblastoma.  
26. Nardi W, Nyla N, El Zein S, Tzanis D, Buhadiba T, Helfre S, et al.  
DiagnosꢀcAccuracyandsafetyofpercutaneouscoreneedlebiopsy  
of retroperitoneal tumors. Eur J Surg Oncol. 2024;50(1):107298.  
doi:10.1016/j.ejso.2023.107298.  
27. Coindre J, Terrier P, Bui N, Bonichon F, Collin, Le Doussal V F. et  
al. Prognosꢀc factors in adult paꢀents with locally controlled  
soꢁ ꢀssue sarcoma. A study of 546 paꢀents from the French  
1
1
3. Lee S, Goh B, Teo M, Chew M, Chow P, Wong K et al. Retroperitoneal  
4. Shibata D, Lewis J, Leung D, Brennan M. Is there a role for  
incomplete resecꢀon in the management of retroperitoneal  
1
5. Abdelfatah E, Guzzeꢂa A, Nagarajan N, Wolfgang C, Pawlik T, Choꢀ  
M, et al. Long-term outcomes in treatment of retroperitoneal  
sarcomas:a 15 year single-insꢀtuꢀon evaluaꢀon of prognosꢀc  
features. J Surg Oncol. 2016;114:56-64 hꢂps://doi.org/10.1002/